Onvansertib in Combination with Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants with Metastatic Pancreatic Ductal Adenocarcinoma
The main objective of this trial is to assess the efficacy of onvansertib in combination with nanoliposomal irinotecan (nal-IRI), leucovorin, and fluorouracil (5-FU) for treatment of participants with histologically confirmed metastatic pancreatic ductal adenocarcinoma (PDAC).
Pancreatic Ductal Adenocarcinoma
DRUG: Onvansertib|DRUG: Nanoliposomal irinotecan|DRUG: Leucovorin|DRUG: Fluorouracil
Overall Response Rate (ORR), Up to 2 years
Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE), Up to 2 years|Duration of Response (DOR), Up to 2 years|Overall Response Rate (ORR) in Participants Who Receive At Least 2 Treatment Cycles, Each cycle is 2 weeks., Up to 2 years|Overall Survival (OS), Up to 2 years|Disease Control Rate (DCR), Up to 2 years|Reduction from Baseline in Serum CA19-9 Response, Baseline up to 2 years
The main objective of this trial is to assess the efficacy of onvansertib in combination with nanoliposomal irinotecan (nal-IRI), leucovorin, and fluorouracil (5-FU) for treatment of participants with histologically confirmed metastatic pancreatic ductal adenocarcinoma (PDAC).